ERLOTINIB
NICE Appraisal
TA162 Erlotinib for the treatment of non-small cell lung cancer (November 2008)
DSU Reports
The risk and costs of febrile neutropenia in patients with non-small cell lung cancer treated with docetaxel (December 2007)
Related publications
A Wailoo, A Sutton, A Morgan, The risk of febrile neutropenia in patients with non-small cell lung cancer treated with Docetaxel: a systematic review and meta-analysis 2009 British Journal of Cancer Vol 100: 436-441